Cargando…

Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae

Unbiased screening of large randomized chemical libraries in vivo is a powerful tool to find new drugs and targets. However, forward chemical screens in zebrafish can be time consuming and usually >99% of test compounds have no significant effect on the desired phenotype. Here, we sought to find...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohnesorge, Nils, Sasore, Temitope, Hillary, Daniel, Alvarez, Yolanda, Carey, Michelle, Kennedy, Breandán N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544088/
https://www.ncbi.nlm.nih.gov/pubmed/31178719
http://dx.doi.org/10.3389/fphar.2019.00508
_version_ 1783423191451959296
author Ohnesorge, Nils
Sasore, Temitope
Hillary, Daniel
Alvarez, Yolanda
Carey, Michelle
Kennedy, Breandán N.
author_facet Ohnesorge, Nils
Sasore, Temitope
Hillary, Daniel
Alvarez, Yolanda
Carey, Michelle
Kennedy, Breandán N.
author_sort Ohnesorge, Nils
collection PubMed
description Unbiased screening of large randomized chemical libraries in vivo is a powerful tool to find new drugs and targets. However, forward chemical screens in zebrafish can be time consuming and usually >99% of test compounds have no significant effect on the desired phenotype. Here, we sought to find bioactive drugs more efficiently and to comply with the 3R principles of replacement, reduction, and refinement of animals in research. We investigated if pooling of drugs to simultaneously test 8–10 compounds in zebrafish larvae can increase the screening efficiency of an established assay that identifies drugs inhibiting developmental angiogenesis in the eye. In a phenotype-based screen, we tested 1,760 small molecule compounds from the ChemBridge DIVERSet™ chemical library for their ability to inhibit the formation of distinct primary hyaloid vessels in the eye. Applying orthogonal pooling of the chemical library, we treated zebrafish embryos from 3 to 5 days post fertilization with pools of 8 or 10 compounds at 10 μM each. This reduced the number of tests from 1,760 to 396. In 63% of cases, treatment showed sub-threshold effects of <40% reduction of primary hyaloid vessels. From 18 pool hits, we identified eight compounds that reduce hyaloid vessels in the larval zebrafish eye by at least 40%. Compound 4-[4-(1H-benzimidazol-2-yl)phenoxy]aniline ranked as the most promising candidate with reproducible and dose-dependent effects. To our knowledge, this is the first report of a self-deconvoluting matrix strategy applied to drug screening in zebrafish. We conclude that the orthogonal drug pooling strategy is a cost-effective, time-saving, and unbiased approach to discover novel inhibitors of developmental angiogenesis in the eye. Ultimately, this approach may identify new drugs or targets to mitigate disease caused by pathological angiogenesis in the eye, e.g., diabetic retinopathy or age-related macular degeneration, wherein blood vessel growth and leaky vessels lead to vision impairment or clinical blindness.
format Online
Article
Text
id pubmed-6544088
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-65440882019-06-07 Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae Ohnesorge, Nils Sasore, Temitope Hillary, Daniel Alvarez, Yolanda Carey, Michelle Kennedy, Breandán N. Front Pharmacol Pharmacology Unbiased screening of large randomized chemical libraries in vivo is a powerful tool to find new drugs and targets. However, forward chemical screens in zebrafish can be time consuming and usually >99% of test compounds have no significant effect on the desired phenotype. Here, we sought to find bioactive drugs more efficiently and to comply with the 3R principles of replacement, reduction, and refinement of animals in research. We investigated if pooling of drugs to simultaneously test 8–10 compounds in zebrafish larvae can increase the screening efficiency of an established assay that identifies drugs inhibiting developmental angiogenesis in the eye. In a phenotype-based screen, we tested 1,760 small molecule compounds from the ChemBridge DIVERSet™ chemical library for their ability to inhibit the formation of distinct primary hyaloid vessels in the eye. Applying orthogonal pooling of the chemical library, we treated zebrafish embryos from 3 to 5 days post fertilization with pools of 8 or 10 compounds at 10 μM each. This reduced the number of tests from 1,760 to 396. In 63% of cases, treatment showed sub-threshold effects of <40% reduction of primary hyaloid vessels. From 18 pool hits, we identified eight compounds that reduce hyaloid vessels in the larval zebrafish eye by at least 40%. Compound 4-[4-(1H-benzimidazol-2-yl)phenoxy]aniline ranked as the most promising candidate with reproducible and dose-dependent effects. To our knowledge, this is the first report of a self-deconvoluting matrix strategy applied to drug screening in zebrafish. We conclude that the orthogonal drug pooling strategy is a cost-effective, time-saving, and unbiased approach to discover novel inhibitors of developmental angiogenesis in the eye. Ultimately, this approach may identify new drugs or targets to mitigate disease caused by pathological angiogenesis in the eye, e.g., diabetic retinopathy or age-related macular degeneration, wherein blood vessel growth and leaky vessels lead to vision impairment or clinical blindness. Frontiers Media S.A. 2019-05-24 /pmc/articles/PMC6544088/ /pubmed/31178719 http://dx.doi.org/10.3389/fphar.2019.00508 Text en Copyright © 2019 Ohnesorge, Sasore, Hillary, Alvarez, Carey and Kennedy. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ohnesorge, Nils
Sasore, Temitope
Hillary, Daniel
Alvarez, Yolanda
Carey, Michelle
Kennedy, Breandán N.
Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae
title Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae
title_full Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae
title_fullStr Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae
title_full_unstemmed Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae
title_short Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae
title_sort orthogonal drug pooling enhances phenotype-based discovery of ocular antiangiogenic drugs in zebrafish larvae
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544088/
https://www.ncbi.nlm.nih.gov/pubmed/31178719
http://dx.doi.org/10.3389/fphar.2019.00508
work_keys_str_mv AT ohnesorgenils orthogonaldrugpoolingenhancesphenotypebaseddiscoveryofocularantiangiogenicdrugsinzebrafishlarvae
AT sasoretemitope orthogonaldrugpoolingenhancesphenotypebaseddiscoveryofocularantiangiogenicdrugsinzebrafishlarvae
AT hillarydaniel orthogonaldrugpoolingenhancesphenotypebaseddiscoveryofocularantiangiogenicdrugsinzebrafishlarvae
AT alvarezyolanda orthogonaldrugpoolingenhancesphenotypebaseddiscoveryofocularantiangiogenicdrugsinzebrafishlarvae
AT careymichelle orthogonaldrugpoolingenhancesphenotypebaseddiscoveryofocularantiangiogenicdrugsinzebrafishlarvae
AT kennedybreandann orthogonaldrugpoolingenhancesphenotypebaseddiscoveryofocularantiangiogenicdrugsinzebrafishlarvae